Company intelligence / Profile preview
Atsena Therapeutics
Durham, North Carolina, United Statesatsenatx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Atsena is advancing ATSN-201 for XLRS in Phase 1/2 LIGHTHOUSE trial with encouraging early results in Part A and has initiated Part B. ATSN-101 for LCA1 has secured a partner for global pivotal trial. Updated data from LIGHTHOUSE trial expected later in 2025.
- Therapeutic areas
- OphthalmologyRare Diseases
- Modalities
- Gene therapyAAV-based gene therapy
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
Unnamed partner for ATSN-101 global pivotal trial
Beyond the preview
Go deeper on Atsena Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Atsena Therapeutics.